Pengfei Wang

2020.03-now,       Chongqing University, Hongshen Young Teacher

2017.06-2019.11, University of Copenhagen, Postdoc

2012.09-2017.06, Nanjing University, majored in Biology, Ph.D. 

Medicinal Chemistry

Grants and fundings

National Natural Science Foundation of China 22001025

1.  Wang, P. F., Jensen, A. A., Bunch, L. From Methaqualone and Beyond: Structure–Activity Relationship of 6-, 7-, and 8-Substituted 2, 3-Diphenyl-quinazolin-4(3H)-ones and in Silico Prediction of Putative Binding Modes of Quinazolin-4(3H)-ones as Positive Allosteric Modulators of GABA_A Receptors. ACS Chemical Neuroscience, 2020, 11(24), 4362-4375.

2.  Wang, P. F., Qiu, H. Y., He, Y., Zhu, H. L. Cyclin-dependent Kinase 4/6 Inhibitors for Cancer Therapy: A Patent Review (2015–2019). Expert Opinion on Therapeutic Patents, 2020, 30(10), 795-805.

3.  Wang, P. F., Qiu, H. Y., Zhu, H. L. A Patent Review of BRAF Inhibitors: 2013-2018. Expert Opinion on Therapeutic Patents, 2019, 29(8), 595-603.

4.  Wang, P. F., Wang, Z. F., Qiu, H. Y., Huang, Y., Hu, H. M., Wang, Z. C., Zhu, H. L. Identification and Biological Evaluation of Novel Type II B‐RafV600E Inhibitors. ChemMedChem, 2018, 13(23), 2558-2566.

5.  Wang, P. F., Zhang, Y. J., Wang, D., Hu, H. M., Wang, Z. C., Xu, C., Zhu, H. L. Design, Synthesis, and Biological Evaluation of New B-RafV600E Kinase Inhibitors. Bioorganic & Medicinal Chemistry, 2018, 26(9), 2372-2380.

6.  Wang, P. F., Qiu, H. Y., Wang, Z. F., Zhang, Y. J., Wang, Z. C., Li, D. D., Zhu, H. L. Identification of Novel B-RafV600E Inhibitors Employing FBDD Strategy. Biochemical Pharmacology, 2017, 132, 63-76.